सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation (Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/21/000137 Dated 09.03.2022

To,

M/s Intas Pharmaceuticals Limited
Corporate House; Near Sola Bridge,
S.G. Highway, Thaltej,
Ahmedabad – 380054,
Gujarat, India.

Subject: Application for grant of permission to conduct Phase III clinical trial entitled – "A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Compared with Neupogen Injection in Paediatric Patients Under 6 years of Age with Rhabdomyosarcoma or Wilms' Tumour on Myelosuppressive Chemotherapy (CmT) Regimen" as per Protocol No.: 0298-21, Version 2.0 Date: 25.08.2021- regarding

Ref.: Your Application No. BIO/CT04/FF/2021/28204 dated 22-Sep-2021

Sir,

With reference to your Application No.: BIO/CT04/FF/2021/28204 dated 22-Sep-2021, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

i. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;

ii. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall

be located within the same city or within a radius of 50 kms of the clinical trial site;

iii. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

iv. The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

v. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

vi. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

vii. Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

viii. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;

ix. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;

x. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

xi. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

xii. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

xiii. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to

inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

xiv. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

xv. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

xvi. The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

xvii. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

xviii. It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial with the drug, permission to market this drug in the country will automatically be granted to you.

Yours faithfully,

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.09 15:16:18 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

File. No. BIO/CT/21/000137

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits **M/s Intas Pharmaceuticals Limited,** Corporate House; Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, India, to conduct clinical trial of the new drug or investigational new drug study titled "A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Compared with Neupogen Injection in Paediatric Patients Under 6 years of Age with Rhabdomyosarcoma or Wilms' Tumour on Myelosuppressive Chemotherapy (CmT) Regimen" as per Protocol No.: 0298-21, Version 2.0 Date: 25.08.2021 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 09.03.2022

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=11204 6a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.09 15:16:32 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Names of the new drug or investigational new drug</td><td>Pegfilgrastim (r-DNA origin) Injection 1.5 mg/0.15 mL Pre-filled syringe, 2.5 mg/0.25 mL Pre-filled syringe and 4.0 mg/0.4 mL Pre-filled syringe</td></tr>
<tr><td>Therapeutic class</td><td>Hematopoietic Growth Factors</td></tr>
<tr><td>Dosage form:</td><td>Solution for injection for s.c administration</td></tr>
<tr><td>Composition:</td><td>Pegfilgrastim Injection 1.5 mg/0.15 mL PFS, 2.5 mg/0.25 mL PFS and 4.0 mg/0.4 mL PFS

Each 0.15 mL prefilled syringe contains:
Pegfilgrastim.....1.5 mg
Each 0.25 mL prefilled syringe contains:
Pegfilgrastim.....2.5 mg
Each 0.4 mL prefilled syringe contains:
Pegfilgrastim.....4.0 mg

<table>
<tr><th>Name of Ingredient</th><th>Quantity (1.5 mg / 0.15 mL)</th><th>Quantity (2.5 mg / 0.25 mL)</th><th>Quantity (4 mg / 0.4 mL)</th></tr>
<tr><td>Pegfilgrastim drug substance (r-DNA Origin).....INH</td><td>1.5 mg</td><td>2.5 mg</td><td>4 mg</td></tr>
<tr><td>Glacial Acetic Acid ….. BP/Ph. Eur., USP, JP, IP</td><td>0.09 mg</td><td>0.15 mg</td><td>0.23 mg</td></tr>
<tr><td>Sorbitol ….. NF, BP/Ph. Eur., JP, IP</td><td>7.5 mg</td><td>12.5 mg</td><td>20.0 mg</td></tr>
<tr><td>Polysorbate 20…… USP/NF, Ph. Eur., JP, IP</td><td>0.006 mg</td><td>0.01 mg</td><td>0.016 mg</td></tr>
<tr><td>Sodium Hydroxide …….. NF, BP/Ph. Eur., JP, IP</td><td>0.009 mg</td><td>0.014 mg</td><td>0.023 mg</td></tr>
<tr><td>Water for Injection….I.P./ U.S.P./Ph. Eur./B.P.</td><td>q.s. to 0.15 mL</td><td>q.s. to 0.25 mL</td><td>q.s. to 0.4 mL</td></tr>
</table>
</td></tr>
<tr><td>Indications:</td><td>Paediatric Patients Under 6 years of Age with Rhabdomyosarcoma or Wilms' Tumour on Myelosuppressive Chemotherapy (CmT) Regimen</td></tr>
</table>

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Mahatma Gandhi Cancer Hospital & research Institute, 1/7 MVP colony, Visakhapatnam-530017, Andhra Pradesh, India.	Institutional Review Board Mahatma Gandhi Cancer Hospital Research Institute, 1/7 MVP Colony, Visakhapatnam, Andhra Pradesh - 530017, India EC Reg. No. ECR/529/Inst/AP/2014/RR-20	Dr. Rakesh Reddy Boya
2.	Department of Pediatrics, Sir Ganga Ram Hospital, Sir Ganga Ram Hospital marg, Rajinder nagar, New Delhi, Delhi -110060, India.	Sir Ganga Ram Hospital Ethics Committee, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi, Delhi - 110060, India. EC Reg. No. ECR/20/Inst/DL/2013/RR-19	Dr. Anupam Sachdeva
3.	Kiran Hospital Multi super Speciality Hospital & Research Centre, Near Sumul Dairy, Surat-395004, India	Kiran Hospital Ethics Committee, Kiran Hospital, Near Sumul Dairy,Surat, - 395004, Gujarat, India EC Reg. No. ECR/1029/Inst/GJ/2018/RR-21	Dr. Anshul Agrawal
4.	Deenanath Mangeshkar Hospital and Research Centre, Erandwane, Pune - 411004	Institutional Ethics Committee Deenanath Mangeshkar Hospital and Research Centre, off Karve Road Erandawane, Pune, Maharashtra – 411004, India. EC Reg. No. ECR/15/Inst/Maha/2013/RR-19	Dr. Shailesh Kanvinde